Research programme: onchocerciasis (river blindness) therapies - Anacor

Drug Profile

Research programme: onchocerciasis (river blindness) therapies - Anacor

Alternative Names: River blindness therapies - Anacor/USCF/New York Blood Center

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anacor Pharmaceuticals
  • Developer Anacor Pharmaceuticals; New York Blood Center; University of California at San Francisco
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Onchocerciasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Onchocerciasis in USA
  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 03 Dec 2010 Early research in Onchocerciasis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top